Clinical trials: Herpes Simplex Virus
Healthy
Drug-Drug Interaction Study: ASP2151 and Montelukast
CYP2C8 is involved in the metabolism of many drugs. So, it is important to assess in vivo the inhibitory effect of ASP2151 on that enzyme to determine any possible drug interactions.
- Trial name
- NCT02321748
- Testing
- Montelukast, ASP2151
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
Herpes Zoster, Pneumococcal Infection
ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)
The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are…
- Trial name
- NCT00535730
- Testing
- Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™, Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23
- Volunteers
- 473 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Simplex Oral
EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 20 subjects with documented herpes labialis.
- Trial name
- NCT04893577
- Testing
- EDTA, Abreva
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Herpes Zoster, Varicella-zoster Vaccine
Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)
This study was conducted to obtain safety and immunogenicity data after a booster dose of Zoster Vaccine, Live administered ≥10 years following an initial dose.
- Trial name
- NCT01245751
- Testing
- Zoster Vaccine, Live
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Background: People who have cancer tend to get sick more often. This is in part because of the cancer treatments they get. Because of this, they may get shingles.
- Conditions
- Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT03702231
- Testing
- Zoster Vaccine Recombinant, Adjuvanted
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Herpes Zoster, Herpes Zoster Vaccine
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or…
- Trial name
- NCT02045836
- Testing
- Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 865 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Herpes Zoster Vaccine
Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older
The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70 years.
- Trial name
- NCT01165229
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 213 sites in United States, Australia and 16 more
- Volunteers
- 14,819 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Post Herpetic Neuralgia
Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia
Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice
- Trial name
- NCT01426230
- Where
- 37 sites in United States
- Volunteers
- 201 people
- Sponsor
- Depomed
Shingles
Immune Response to Shingles Vaccination
The purpose of this study is to learn more about the immune response to varicella zoster virus (VZV).
- Trial name
- NCT02624375
- Testing
- Zoster Vaccine Live
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Washington
Herpes Labialis
An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode
This study will treat approximately 24 participants who experience cold sores. Patches will be applied to the cold sore for up to ten days, and the symptoms will be measured during daily clinic visits using non-invasive…
- Trial name
- NCT01653509
- Testing
- Acyclovir patch
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Labialis
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
- Trial name
- NCT00306293
- Testing
- valacyclovir
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ).
- Trial name
- NCT01827839
- Testing
- Herpes Zoster vaccine (GSK1437173A)
- Where
- 4 sites in Canada, Russia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
The purpose of the study is to evaluate the general safety of ZOSTAVAX™ in subjects 60 years of age or older as required by the FDA.
- Trial name
- NCT00550745
- Testing
- Zoster Vaccine, Live
- Volunteers
- 11,999 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)
This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) receiving chemotherapy and to assess the impact of V212 on…
- Trial name
- NCT01254630
- Testing
- V212
- Volunteers
- 5,305 people
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Shingles
ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)
This study will evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ in Korean adults. Approximately 180 herpes zoster history negative subjects ≥ 50 years of age will be enrolled in the study.
- Trial name
- NCT01556451
- Testing
- Zoster Vaccine Live
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Simplex
Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients
The purpose of this study is to evaluate the preventive efficacy for HSV infection and safety of valaciclovir (VACV) in the adult and pediatric HSCT patients.
- Trial name
- NCT01602562
- Testing
- VACV tablets (Adults or pediatrics) or granules (pediatrics)
- Where
- 11 sites in Japan
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects
The subjects included in this study are subjects that participated in study NCT00434577. These subjects were vaccinated with the candidate Herpes Zoster (HZ) vaccine at Month 0 and Month 2 and were then followed at Month 12…
- Trial name
- NCT01295320
- Testing
- Blood sample
- Where
- 11 sites in Czechia, Germany and 2 more
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Genitalis
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more…
- Trial name
- NCT00158860
- Testing
- Valaciclovir
- Where
- 72 sites in United States, Argentina and 3 more
- Volunteers
- 384 people
- Sponsor
- GlaxoSmithKline
Herpes Simplex Oral
Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions
This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 40 subjects with documented herpes labialis.
- Trial name
- NCT06558838
- Testing
- acyclovir-penciclovir cream, Abreva
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Utah